GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » Total Current Liabilities

Cannara Biotech (STU:8CB0) Total Current Liabilities : €21.52 Mil (As of Feb. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cannara Biotech's total current liabilities for the quarter that ended in Feb. 2025 was €21.52

Cannara Biotech Total Current Liabilities Historical Data

The historical data trend for Cannara Biotech's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Total Current Liabilities Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Total Current Liabilities
Get a 7-Day Free Trial 2.22 4.61 9.06 14.41 17.94

Cannara Biotech Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.26 18.12 17.94 24.61 21.52

Cannara Biotech Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cannara Biotech's Total Current Liabilities for the fiscal year that ended in Aug. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=11.532+6.313
+Other Current Liabilities+Current Deferred Liabilities
=0+0.09
=17.94

Cannara Biotech's Total Current Liabilities for the quarter that ended in Feb. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=11.303+9.925
+Other Current Liabilities+Current Deferred Liabilities
=0.00099999999999767+0.29
=21.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cannara Biotech Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » Total Current Liabilities
Comparable Companies
TSX:XLY XCNQ:PLTH TSX:CRDL TSXV:SBBC XCNQ:GRIN TSXV:RX TSX:MDP XCNQ:JUSH XCNQ:AAWH.U TSX:HLS ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
LOVFF:USA 8CB0:Germany LOVE:Canada
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Website
http://www.cannara.ca
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Cannara Biotech Headlines

No Headlines